Lung Cancer Clinical Trials

Find Lung Cancer Clinical Trials Near You

A Targeted Ablation and Resection Study With Galvanize Aliya® EX Pulsed Electric Field (PEF) Technology

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

A prospective, single-arm, non-randomized, single-center, open-label, treat and resect study following patients through surgical resection. The study is designed to evaluate the safety and feasibility of the Aliya EX System for the ablation of pulmonary lesions using pulsed electric field (PEF) energy delivery. The study is intended for adult patients with suspected or confirmed pulmonary malignant lesion(s) ≥1.5 cm to ≤4 cm whom are surgical candidates and have not received treatment for the index tumor in the last two years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Presence of at least one lesion in the lung measuring ≥ 1.5 cm and ≤ 4 cm diameter by computed tomography (CT) size estimate deemed suitable for PEF ablation per institutional guidelines.

• High probability of malignancy as determined by the investigator.

• Patient has been deemed a candidate for definitive lung tissue resection per institutional SOC.

• Patient is, in the opinion of the Principal Investigator (PI), able to adhere to and undergo the PEF and surgical procedures.

• Patient is able to tolerate general anesthesia.

• Patient is 18 years of age or older.

• Patient has provided informed consent.

Locations
Other Locations
Hong Kong Special Administrative Region
Prince of Wales Hospital
RECRUITING
Shatin
Contact Information
Primary
Maria Plentl, MSN
mplentl@galvanizetx.com
(650) 268-4252
Backup
Partha Seshaiah, PhD
pseshaiah@galvanizetx.com
(650) 268-4252
Time Frame
Start Date: 2026-03-13
Estimated Completion Date: 2027-02-28
Participants
Target number of participants: 25
Treatments
Experimental: Treatment
Single treatment arm-PEF
Related Therapeutic Areas
Sponsors
Leads: Galvanize Therapeutics, Inc.

This content was sourced from clinicaltrials.gov